RT期刊文章SR电子T1早期缺血性中风后肌钙蛋白水平升高表明Cardioembolic源(P4.031)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P4.031 VO 90 15 A1安德鲁·d . Chang A1布列塔首页尼补充a·里奇A1恩典b Russo A1 Mahesh诉Jayaraman A1瑞安a -麦克塔加特A1摩根Hemendinger A1 Priya独角鲸A1凯蒂Dakay A1布莱恩MacGrory A1 (Shawna m .切割A1蒂娜·m·伯顿A1克里斯托弗·歌A1埃米尔Mehanna A1马修Siket A1特雷西·e·马德森A1迈克尔Reznik A1亚历山大·e·merkle A1迈克尔·p·Lerario A1 Hooman Kamel A1米切尔SV。艾尔金德A1凯伦·l·富里A1 Shadi Yaghi年2018 UL //www.ez-admanager.com/c首页ontent/90/15_Supplement/P4.031.abstract AB目的:探讨早期缺血性中风后肌钙蛋白水平升高是否可以用作标记的栓塞中风亚型(cardioembolic (CE)和栓塞性中风的未知来源[、因])而不是non-cardioembolic亚型(大血管疾病、小血管疾病等)。背景:心肌肌钙蛋白升高是心脏病的一个标志,最近被证明与栓塞中风的风险有关。设计/方法:我们从未来的缺血性中风数据库和抽象数据包括所有缺血性中风患者在22个月的时间。每我们的实验室,我们定义积极的肌钙蛋白≥0.1 ng / mL和中间一样≥0.06 ng / mL和消极< 0.1 ng / mL。未经调整的,调整后的回归模型建立来确定中风亚型之间的关系(、因和CE)和积极的和中间肌钙蛋白水平,调整关键混杂因素包括人口统计数据(年龄和性别),临床特征(高血压、高脂血症、糖尿病、肾功能、冠心病、充血性心力衰竭,目前的吸烟,署分数),心脏变量(左心房直径,壁运动异常,射血分数,和公关间隔心电图),和孤立的梗塞。结果:我们确定了1234名患者,其中1129年入学肌钙蛋白水平可用;10.0%(113/1129)有一个积极的肌钙蛋白。全面调整模型,,有一个协会之间的肌钙蛋白亚型积极性和、因(调整后的优势比[或]4.46,95%可信区间(CI) 1.03 - -7.97, p = 0.003)和CE中风亚型(或5.00;95%可信区间1.83 - -13.63;p = 0.002)。没有中间肌钙蛋白水平和之间的联系、因或CE中风亚型。Conclusions: We found that early positive troponin after ischemic stroke may be independently associated with a cardiac embolic source. Future studies are needed to confirm our findings using high sensitivity troponin assays and to test optimal secondary prevention strategies in patients with ESUS and positive troponin.Disclosure: Dr. Chang has nothing to disclose. Dr. Ricci has nothing to disclose. Dr. Russo has nothing to disclose. Dr. Jayaraman has nothing to disclose. Dr. McTaggart has nothing to disclose. Dr. Hemendinger has nothing to disclose. Dr. Narwal has nothing to disclose. Dr. Dakay has nothing to disclose. Dr. Mac Grory has nothing to disclose. Dr. Cutting has nothing to disclose. Dr. Burton has nothing to disclose. Dr. Song has nothing to disclose. Dr. Mehanna has nothing to disclose. Dr. Siket has nothing to disclose. Dr. Madsen has nothing to disclose. Dr. Reznik has nothing to disclose. Dr. Merkler has nothing to disclose. Dr. Lerario has nothing to disclose. Dr. Kamel has nothing to disclose. Dr. Elkind has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott, Boehringer-Ingelheim, Merck/Organon, Hi-Tech Pharmaceuticals, and Auxilium. . Dr. Furie has nothing to disclose. Dr. Yaghi has nothing to disclose.